Back to Journals » Vascular Health and Risk Management » Volume 5

Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin

Authors Robinson J

Published 4 December 2008 Volume 2009:5 Pages 31—43


Review by Single anonymous peer review

Peer reviewer comments 3

Download Article [PDF] 

Jennifer G Robinson

University of Iowa, Iowa City, IA, USA

Abstract: ER niacin combined with simvastatin provides an additional option for achieving LDL-C and non-HDL-C goals for cardiovascular prevention, with greater efficacy in those with triglyceride levels >200 mg/dL. ER niacin 1000 mg combined with simvastatin 20 mg reduced LDL-C by 6%, non-HDL-C by 7%, and triglycerides by 13%, and raised HDL-C by 11% compared to simvastatin 20 mg alone. The 2000 mg dose combined with simvastatin 20 to 40 mg raised reduced LDL-C by 7% to 24%, non-HDL-C by 16% to 28%, and triglycerides by 23% to 34%, and increased HDL-C by 18% to 22% compared to similar dose simvastatin therapy. While cardiovascular risk is reduced in proportion to the magnitude of LDL-C lowering, the additive benefit of raising HDL-C and lowering triglycerides remains to be determined. ER niacin-simvastatin is reasonably well tolerated, with a <7% discontinuation rate due to flushing in patients who used aspirin or non-steroidal anti-inflammatory medications as needed. However, drop-out rates were high in both the simvastatin and ER niacin–simvastatin treatment groups in both the 24- and 52-week studies. The safety profile of the combination appears to be similar to that of niacin and simvastatin used as monotherapies. Results of ongoing morbidity/mortality trials of ER niacin added to statin therapy are eagerly awaited.

Keywords: simvastatin, niacin, fixed-dose, dyslipidemia

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]